Opicapone Treatment Initiation Open-Label Study
Sponsor:Neurocrine BiosciencesBrief Summary: This is an observational study to describe the treatment patterns and clinical outcomes observed with use of…
[searchandfilter fields="search,category" post_types="post"]
Adaptive Neurostimulation to Restore Sleep in Parkinson’s Disease: An Investigation of STN LFP Biomarkers in Sleep Dysregulation and Repair
Sponsor:University of NebraskaBrief Summary: Parkinson's disease (PD) is a neurodegenerative disorder that leads to both motor and non-motor symptoms. Therapies…
Cutaneous Phosphorlyated α-synuclein Detection as a Biomarker of Synucleinopathy
Sponsor:CND Life SciencesBrief Summary: The Synuclein-One Study will be evaluating α-synuclein in patients with Parkinson's disease, Multiple System Atrophy, Dementia…
Auricular Muscle Zone Stimulation for Parkinson Disease (Earstim-PD)
Sponsor:Stoparkinson Healthcare Systems LLCBrief Summary: A Multicenter, Randomized, Blinded, Electronic Device in Subjects with Parkison Disease. Criteria Inclusion Criteria: 1.…
Real-Time Levodopa Monitoring for Improved Management of Parkinson Disease
Sponsor:University of California, San DiegoBrief Summary: This project aims to develop a minimally invasive microneedle sensor to monitor levodopa levels…
Adaptive Cortical and Subcortical Brain Stimulation to Improve Motor Behaviors and Gait in Parkinson’s Disease
Sponsor:University of California, San FranciscoBrief Summary: This is a single-center phase I clinical study aiming to improve gait functions in…
An Open-Label Extension Of Study M15-736 To Evaluate The Safety And Tolerability Of 24-Hour Daily Exposure Of ABBV-951 In Subjects With Advanced Parkinson’s Disease
Sponsor:AbbVieBrief Summary: Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how…
A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2a Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral UCB0599 in Study Participants With Early Parkinson’s Disease
Sponsor:UCB Biopharma SRLBrief Summary: The purpose of the study is to assess the safety and tolerability of UCB0599 and to…
A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson’s Disease
Sponsor:Hoffmann-La RocheBrief Summary: This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous…
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson’s Disease Experiencing Motor Fluctuations (BouNDless)
Sponsor:NeuroDerm Ltd.Brief Summary: This is a multi-center, randomized, double blind, active controlled clinical Study. Following a screening period, eligible subjects…
